ImmunoID NeXT

7 Jul, 2020

2020 AACR: Composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients

2020 AACR: Composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients Checkpoint inhibitor therapy has demonstrated meaningful, if varied, antitumor activity, with patient response influenced by a variety of biological factors, including complex interactions between the tumor and immune system. Thus, [...]

7 Jul, 2020

2020 AACR: Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome

2020 AACR: Quantification of tumor-infiltrating immune cell populations with an augmented transcriptome Comprehensive characterization of the tumor and tumor microenvironment (TME) can improve our understanding of tumor progression and treatment outcomes. In particular, quantification of the immune infiltrate has the potential to inform mechanisms of immune escape and predict response to therapy. Standard experimental [...]

7 Jul, 2020

2020 AACR: Precision neoantigen discovery using a pan-predictive machine learning model integrated into ImmunoID NeXT Platform®

2020 AACR: Precision neoantigen discovery using a pan-predictive machine learning model integrated into ImmunoID NeXT Platform® Technologies for neoantigen discovery are critical for developing personalized cancer vaccines and neoantigen-based biomarkers. Precision neoantigen discovery entails comprehensive detection of tumor-specific genomic variants and accurate prediction of MHC presentation of epitopes originating from such variants. Our ImmunoID [...]

7 Jul, 2020

2020 AACR: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance mechanism to anti-PD-1 therapy

2020 AACR: Sensitive HLA loss of heterozygosity detection reveals allele-specific neoantigen expansion as resistance Loss of heterozygosity (LOH) in the HLA locus is increasingly being recognized as an important mechanism of immune escape and a proposed biomarker for immunotherapy response. Neoantigens that bind to a deleted HLA allele will no longer be presented to [...]

5 Nov, 2018

ImmunoID NeXT brochure

ImmunoID NeXT™ The Universal Cancer Immunogenomics Platform ImmunoID NeXT is designed specifically to enable the development of more efficacious cancer immunotherapies and the next-generation of composite biomarkers to better predict patient response. While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and [...]

Go to Top